Latest news with #FUJIFILMCorporation
TECHx
14 hours ago
- Business
- TECHx
FUJIFILM Launches instax mini 41 in Middle East
Home » Product Watch » FUJIFILM Launches instax mini 41 in Middle East FUJIFILM Corporation has announced the launch of the 'instax mini 41™,' a new entry-level model in its popular instax series of instant cameras. The new model will be available across the Middle East starting May 27, 2025. The instax mini 41 is an analog instant camera that builds on the success of the mini 40™. It features a similar classic design while adding a sleek and stylish look. The camera comes in black and dark-toned silver with a touch of orange, making it visually appealing and fashionable to carry. FUJIFILM revealed that the mini 41 is not just about looks. It includes several enhancements for better performance. Key features include: Close-up Mode to reduce discrepancies between the viewfinder and print area. Automatic Light Adjustment to optimize exposure for any scene. The mini 41 automatically adjusts shutter speed and flash output based on lighting conditions. As a result, users can capture well-lit, clear photos in various settings indoors, outdoors, and even in low light. When users rotate the lens, the Close-up Mode activates instantly. This feature is ideal for close-up shots and selfies. Additionally, a Selfie Mirror next to the lens allows users to check their composition before taking a photo. The bottom of the camera has a textured finish for a secure grip, enhancing usability. FUJIFILM reported that the camera is designed to be both functional and fashionable. The promotional tagline 'develop your style' is being used online, on social media, and in stores to communicate the product's appeal. FUJIFILM aims to position the mini 41 as a stylish accessory in addition to a camera. The retail price is set at $99 USD, although it may vary by country and retailer. FUJIFILM confirmed its commitment to expanding the instax brand and encouraging on-the-spot photo printing for users across all age groups.
Business Wire
19-05-2025
- Business
- Business Wire
Fujifilm Validates Cancer Cell-Targeting Potential of Peptide Oligonucleotide Conjugates with Novel Cyclic Peptides
TOKYO--(BUSINESS WIRE)--FUJIFILM Corporation announces the successful validation of the cancer cell-targeting potential of its peptide-oligonucleotide conjugates. This validation resulted from combining oligonucleotides with cyclic peptides developed from Fujifilm's proprietary peptide library, which contains trillions of variants. This research achievement will be presented at TIDES USA, an exhibition to be held from May 19 to 22, 2025, in San Diego (poster number: 35). Cyclic peptides, including those containing unnatural amino acids, are emerging as a promising new modality in drug discovery due to their unique and favorable properties, including high binding affinity and specificity, improved tissue permeability, and synthetic versatility. Peptide-oligonucleotide conjugation addresses delivery challenges associated with oligonucleotide-based therapies by utilizing the excellent delivery properties of peptides and have been actively researched. Leveraging its large peptide library constructed with mRNA display technology, and structural optimization techniques, Fujifilm has developed a proprietary cyclic peptide that binds strongly to integrins overexpressed on the surface of cancer cells, with a low dissociation constant (K D) of 1.6 nM. Utilizing chemical modification methods Fujifilm can successfully synthesize the peptide-oligonucleotide conjugate at high yield. Uptake of these peptide-oligonucleotide conjugates by cancer cells is higher compared to uptake of the non-conjugated oligonucleotide, demonstrating the peptide-oligonucleotide conjugate's ability to selectively accumulate in cancer cells. Fujifilm is expanding its drug discovery services for peptide therapeutics globally, providing a wide range of contract research services focusing on peptide discovery, high-throughput screening, and structural optimization. Fujifilm's one-stop comprehensive service includes peptide chemical synthesis and target protein expression and purification to meet diverse research demands. Fujifilm is committed to driving research and development that fosters technological innovation in the healthcare field, leveraging the ability of cyclic peptides to regulate cellular functions and their specific molecular recognition capabilities, contributing to the advancement of pharmaceutical development of peptide therapeutics.
